
Cardiovascular disease (CVD) is a significant mortality factor in men with prostate cancer (PC). This narrative review analyzed recent literature from 2000 to 2024 on the impact of PC treatments on cardiovascular health. Findings indicate that therapies such as androgen deprivation, taxane-based chemotherapy, and GnRH-axis targeting may elevate CVD risks. The review emphasizes the need for preventative strategies and multidisciplinary care to address CVD in PC survivors. Future research directions include exploring cardiotoxicity mechanisms and improving survivorship by mitigating non-oncologic mortality.
Like
Save
Share